Showing results (201-210 of 214) with videos related to

Sort By:
Pageof 22
The Journal of Infectious Diseases|August 8, 2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical StudiesGolnaz Namazi, Jesse M Fajnzylber, Evgenia Aga, et al.
Nature Communications|October 6, 2022
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2Elizabeth M Parzych, Jianqiu Du, Ali R Ali, et al.
Nature Medicine|September 8, 2020
Recommendations for measuring HIV reservoir size in cure-directed clinical trialsMohamed Abdel-Mohsen, Douglas Richman, Robert F Siliciano, et al.
Science Translational Medicine|April 20, 2018
CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cellsMohamed Abdel-Mohsen, Leticia Kuri-Cervantes, Judith Grau-Exposito, et al.
The Journal of Infectious Diseases|January 26, 2022
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label TrialKimberly A Kraynyak, Elliott Blackwood, Joseph Agnes, et al.
Eclinicalmedicine|January 4, 2021
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trialPablo Tebas, ShuPing Yang, Jean D Boyer, et al.
The Journal of Clinical Investigation|November 17, 2021
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumoniaKatharine J Bar, Pamela A Shaw, Grace H Choi, et al.
JCI Insight|February 24, 2025
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infectionMyra Happe, Rebecca M Lynch, Carl J Fichtenbaum, et al.
The New England Journal of Medicine|December 14, 2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment InterruptionKatharine J Bar, Michael C Sneller, Linda J Harrison, et al.
The Lancet. HIV|March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meetingBoris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Pageof 22